Skip to content
Telehealth Graded
State guide

Kentucky Medicaid and GLP-1s

Kentucky's GLP-1 criteria open with a limit on changing your mind. Two brand switches a year, then you stay put. Everything else on the page is diabetes: a confirmed type 2 diagnosis, an A1c to match, a thyroid-cancer history check, and a footnote under each block saying drugs used for weight loss are excluded. The state's drug list names no weight-management GLP-1 anywhere.

Every source on this page was read first-hand in September 2026, and each one below carries the date printed on the document itself.

2
documents cited
6
sourced facts
2
primary sources

What changed, and what the document says

  1. Two brand switches a year

    Conditions apply

    A supply-and-cost rule written as a clinical one. It caps how often you can move between products, whatever the reason.

    NOTE: GLP-1 medications are limited to two brand switches per year.

    Kentucky Medicaid (MedImpact clinical document)VERSION: SEPTEMBER 2026

  2. Six months at a time

    Conditions apply

    Every approval in the class runs on the same half-year clock.

    Approval Duration: 6 months

    Kentucky Medicaid (MedImpact clinical document)VERSION: SEPTEMBER 2026

  3. The exclusion is a footnote, repeated

    Not covered

    It appears under each criteria block rather than once at the top, which is how it survives someone reading only their own drug's page.

    *Drugs used for anorexia, weight loss, or weight gain are excluded

    Kentucky Medicaid (MedImpact clinical document)VERSION: SEPTEMBER 2026

  4. A thyroid-cancer history bars the class

    Conditions apply

    Kentucky puts the label's boxed contraindication into the coverage criteria, so it is checked by the payer and not only the prescriber.

    No personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2

    Kentucky Medicaid (MedImpact clinical document)VERSION: SEPTEMBER 2026

  5. An A1c that matches the diagnosis

    Conditions apply

    A diagnosis code alone will not do it; the number has to agree with the code.

    A1c lab value that correlates to a T2DM diagnosis

    Kentucky Medicaid (MedImpact clinical document)VERSION: SEPTEMBER 2026

  6. No weight-management GLP-1 on the list

    Not covered

    All 2,300 non-blank lines of the September 2026 drug list were read. Wegovy, Zepbound and Saxenda appear nowhere on it, and neither do the words obesity or weight loss — while the diabetes GLP-1s are all present, which is what proves the scan works.

    Kentucky Medicaid – Preferred Drug List (PDL)

    Kentucky Medicaid (MedImpact, the single-PDL pharmacy benefit manager)September 2026

What the state didn't publish

No GLP-1 approved for weight management appears anywhere on Kentucky's Medicaid drug list, and neither do the words obesity or weight loss.

We looked at 2300 documents to say that — All 2,300 non-blank lines of the Preferred Drug List dated September 2026, read as text end to end.

The identical scan, in the same run, over the same 2,300 lines: Ozempic 2, metformin 17, insulin 15, Mounjaro 1, Trulicity 1, Victoza 1, Rybelsus 1, liraglutide 1. The ruler finds GLP-1 brand names on this document — which is exactly the kind of token Wegovy and Zepbound are — and against those same lines Wegovy, Zepbound, Saxenda, obesity, weight loss, anti-obesity, phentermine and orlistat each returned zero.

Checked September 2026 against Kentucky Medicaid – Preferred Drug List (PDL), Kentucky Medicaid (MedImpact, the single-PDL pharmacy benefit manager).

Which of these companies serve Kentucky?

Of the 242 companies we grade, 25 publish a list of the states they are licensed in. We checked 214 more and found no such list on any page we read; 3 we have not checked either way.

18 of those lists name Kentucky: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon and Peak Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Sources

Each document below was fetched and read on the date shown beside it, which is the date printed on the document — not always the date in its web address. All of them were read in September 2026, the same session as the rest of this page.

Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.